


AVIRAGEN[®] THERAPEUTICS

Aviragen Therapeutics, Inc.
Investor Relations Department
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: AVIR

Last Trade:	0.60
Trade Time:	3:57 PM ET Jul 20, 2017
Change:	0.02  (+3.226%)
Day Range	0.58 - 0.61
52-Week Range	0.43 - 2.00
Volume	188,461

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: vapidavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplavir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papill... [\(more\)](#)

Stock Information



Press Releases [\[View all \]](#)

May 4, 2017

[Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results](#)

Apr 4, 2017

[Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update](#)

Feb 13, 2017

[Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapidavir](#)

Feb 2, 2017

[Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results](#)

Feb 1, 2017

[Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Sep 13, 2016

[Annual Report \(10-K\)](#)

Sep 27, 2016

[Proxy Statement \(DEF 14A\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Feb 6, 2017

[Quarterly Report \(10-Q\)](#)

Nov 8, 2016

[Quarterly Report \(10-Q\)](#)